These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32108355)

  • 1. Recombinant human insulin-like growth factor-1 therapy for 6 months improves growth but not motor function in boys with Duchenne muscular dystrophy.
    Rutter MM; Wong BL; Collins JJ; Sawnani H; Taylor MD; Horn PS; Backeljauw PF
    Muscle Nerve; 2020 May; 61(5):623-631. PubMed ID: 32108355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.
    Mah JK; Clemens PR; Guglieri M; Smith EC; Finkel RS; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; McDonald CM; Damsker JM; Schwartz BD; Mengle-Gaw LJ; Jackowski S; Stimpson G; Ridout DA; Ayyar-Gupta V; Baranello G; Manzur AY; Muntoni F; Gordish-Dressman H; Leinonen M; Ward LM; Hoffman EP; Dang UJ;
    JAMA Netw Open; 2022 Jan; 5(1):e2144178. PubMed ID: 35076703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion.
    Woods KA; Camacho-Hübner C; Bergman RN; Barter D; Clark AJ; Savage MO
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1407-11. PubMed ID: 10770174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human growth hormone plus recombinant human insulin-like growth factor-1 coadministration therapy in short children with low insulin-like growth factor-1 and growth hormone sufficiency: results from a randomized, multicenter, open-label, parallel-group, active treatment-controlled trial.
    Backeljauw PF; Miller BS; Dutailly P; Houchard A; Lawson E; Hale DE; Reiner B; Sperling MA;
    Horm Res Paediatr; 2015; 83(4):268-79. PubMed ID: 25765099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy.
    Kao KT; Joseph S; Capaldi N; Brown S; Di Marco M; Dunne J; Horrocks I; Shepherd S; Ahmed SF; Wong SC
    Eur J Pediatr; 2019 May; 178(5):633-640. PubMed ID: 30762116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence of muscle loss delay and improvement of hyperinsulinemia and insulin resistance in Duchenne muscular dystrophy supplemented with omega-3 fatty acids: A randomized study.
    Rodríguez-Cruz M; Atilano-Miguel S; Barbosa-Cortés L; Bernabé-García M; Almeida-Becerril T; Cárdenas-Conejo A; Del Rocío Cruz-Guzmán O; Maldonado-Hernández J
    Clin Nutr; 2019 Oct; 38(5):2087-2097. PubMed ID: 30420291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure.
    Rutter MM; Collins J; Rose SR; Woo JG; Sucharew H; Sawnani H; Hor KN; Cripe LH; Wong BL
    Neuromuscul Disord; 2012 Dec; 22(12):1046-56. PubMed ID: 22967789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
    Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial.
    Hafner P; Bonati U; Rubino D; Gocheva V; Zumbrunn T; Gueven N; Fischer D
    Trials; 2016 Aug; 17(1):389. PubMed ID: 27488051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
    Tian C; Wong BL; Hornung L; Khoury JC; Miller L; Bange J; Rybalsky I; Rutter MM
    Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.
    Mercuri E; Signorovitch JE; Swallow E; Song J; Ward SJ; ;
    Neuromuscul Disord; 2016 Sep; 26(9):576-83. PubMed ID: 27423700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Associated With Early Motor Function Trajectories in DMD After Glucocorticoid Initiation: Post Hoc Analysis of the FOR-DMD Trial.
    Schiava M; McDermott MP; Broomfield J; Abrams KR; Mayhew AG; McDonald CM; Martens WB; Gregory SJ; Griggs RC; Guglieri M;
    Neurology; 2024 May; 102(10):e209206. PubMed ID: 38710006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy.
    Goemans N; Vanden Hauwe M; Signorovitch J; Swallow E; Song J;
    PLoS One; 2016; 11(10):e0164684. PubMed ID: 27737016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Clemens PR; Perlman SJ; Smith EC; Horrocks I; Finkel RS; Mah JK; Deconinck N; Goemans N; Haberlova J; Straub V; Mengle-Gaw LJ; Schwartz BD; Harper AD; Shieh PB; De Waele L; Castro D; Yang ML; Ryan MM; McDonald CM; Tulinius M; Webster R; McMillan HJ; Kuntz NL; Rao VK; Baranello G; Spinty S; Childs AM; Sbrocchi AM; Selby KA; Monduy M; Nevo Y; Vilchez-Padilla JJ; Nascimento-Osorio A; Niks EH; de Groot IJM; Katsalouli M; James MK; van den Anker J; Damsker JM; Ahmet A; Ward LM; Jaros M; Shale P; Dang UJ; Hoffman EP
    JAMA Neurol; 2022 Oct; 79(10):1005-1014. PubMed ID: 36036925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of recombinant human growth hormone for 1 year on body composition and muscle strength in children on long-term steroid therapy: randomized controlled, delayed-start study.
    Simon D; Alberti C; Alison M; Le Henaff L; Chevenne D; Boizeau P; Canal A; Ollivier G; Decostre V; Jacqz-Aigrain E; Carel JC; Czernichow P; Hogrel JY
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2746-54. PubMed ID: 23626006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor-I treatment in primary growth hormone insensitivity: effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-binding protein-3 complex.
    Tonella P; Flück CE; Mullis PE
    Horm Res Paediatr; 2010; 73(2):140-7. PubMed ID: 20190552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance.
    Cusi K; DeFronzo R
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3077-84. PubMed ID: 10999789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.